Vascular News and Research

RSS

RFA causes less post-procedural pain in patients with varicose veins: Study

Patients who received radiofrequency ablation for varicose veins reported less post-procedural pain than those treated with endovenous laser ablation. However, both groups reported the same clinical and quality of life improvements at six weeks.

17 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Foundation Venture Capital Group makes initial investment of $175,000 to develop test to diagnose AD

As many as 5.3 million Americans, and 35 million people worldwide, are living with Alzheimer's disease, a devastating neurodegenerative illness characterized by memory loss, cognitive decline and widespread destruction of neurons in the brain. Today, there is no definitive diagnosis for the disease, and no treatment to cure it.

15 May 2010

PLC Systems reports total revenues of $1,062,000 for first-quarter 2010

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three-month period ended March 31, 2010.

14 May 2010

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

BioSphere Medical, Inc. - the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - today reported that it has entered into an a definitive agreement and plan of merger with Merit Medical Systems, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co. in a cash transaction valued at approximately $96 million.

14 May 2010

Merit Medical Systems to acquire BioSphere Medical

Merit Medical Systems, Inc. today announced that it has signed a definitive merger agreement to acquire BioSphere Medical, Inc. in an all cash transaction valued at approximately $96 million, inclusive of all common equity and Series A Preferred preferences.

14 May 2010

Boston Scientific's ACUITY Break-Away Lead Delivery System receives FDA clearance

Boston Scientific Corporation today announced U.S. Food and Drug Administration clearance of the ACUITY Break-Away Lead Delivery System for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, both of which treat heart failure.

14 May 2010

Report describes imaging features of superior mesenteric artery aneurysm

A recent case report published on May 14, 2010 in World Journal of Gastroenterology describes the imaging features of a ruptured superior mesenteric artery aneurysm,which created a giant hematoma and mimicked a pancreatic mass, with mild dilatation of main pancreatic duct.

13 May 2010

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific Corporation today announced it has received CE Mark approval for its TAXUS Element Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent technology. This approval includes a specific indication for the treatment of diabetic patients.

13 May 2010

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.

13 May 2010

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, has received CE Mark approval for its TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System, Boston Scientific's third-generation drug-eluting stent (DES) technology.

13 May 2010

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

12 May 2010

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

Anti-inflammatory drugs appear to help block the rapid kidney destruction that can occur with hypertension, Medical College of Georgia researchers report.

12 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

12 May 2010

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to the Company's LATITUDE® Patient Management system. The LATITUDE system enables physicians to remotely monitor patients with implantable cardiac devices. The upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data.

12 May 2010

$2.8 billion U.S. peripheral vascular device market to grow to over $5.3 billion by 2016

According to a new report by iData Research, the leading authority in medical device and pharmaceutical market research, the U.S. peripheral vascular device market is worth $2.8 billion with expected growth to over $5.3 billion by 2016. Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) are the main drivers of this market, particularly in the stent-graft and peripheral vascular stent segments. These markets are both expected to exceed $1 billion by 2016.

11 May 2010

China Pharma first-quarter revenue up 16% to $15.1 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the first quarter ended March 31, 2010.

11 May 2010

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

The scientific evidence linking air pollution to heart attacks, strokes and cardiovascular death has "substantially strengthened," and people, particularly those at high cardiovascular risk, should limit their exposure, according to an updated American Heart Association scientific statement.

11 May 2010

Folic acid supplement may improve blood flow in young amenorrheic runners

A study led by sports medicine researcher Anne Hoch, D.O. at The Medical College of Wisconsin in Milwaukee has found that oral folic acid may provide a safe and inexpensive treatment to improve vascular function in young female runners who are amenorrheic (not menstruating).

11 May 2010

Vascular News and Research

RFA causes less post-procedural pain in patients with varicose veins: Study

Athersys presents data supporting MultiStem programs

Foundation Venture Capital Group makes initial investment of $175,000 to develop test to diagnose AD

PLC Systems reports total revenues of $1,062,000 for first-quarter 2010

BioSphere Medical to merge with Merit Medical Systems, Merit BioAcquisition

Merit Medical Systems to acquire BioSphere Medical

Boston Scientific's ACUITY Break-Away Lead Delivery System receives FDA clearance

Report describes imaging features of superior mesenteric artery aneurysm

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

$2.8 billion U.S. peripheral vascular device market to grow to over $5.3 billion by 2016

China Pharma first-quarter revenue up 16% to $15.1 million

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

Folic acid supplement may improve blood flow in young amenorrheic runners

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News